Ixekizumab as treatment of erythrodermic psoriasis

Trovato, Emanuele; Orsini, Corinne; Russo, Filomena; Cortonesi, Giulio; Rubegni, Pietro

doi:10.1111/dth.14868

Cited by 7 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…85 Its use in EP management has been reported by clinical trials [39][40][41] and reallife experiences. [42][43][44][45][46] Saeki et al reported the results of a 24-week, multicenter, phase III study enrolling eight patients (seven male, 87.5%; mean age 50.2 ± 12.9) with EP undergoing treatment with ixekizumab (160 mg at baseline followed by 80 mg every 2 weeks up to week 12 and 80 mg every 4 weeks thereafter). 39 At baseline, mean PASI was 42.8 ± 11.6.…”

Section: Ixekizumabmentioning

confidence: 99%

“…41 These results are in line with several case series and case reports. [42][43][44][45][46] Of note, Lo et al 42 reported the results of a case series enrolling nine patients (seven male, 77.8%; mean age: 45.9 ± 13.4 years) with EP previously treated with secukinumab. Globally, PASI75 and PASI90 were reached by 4 (44.4%) and 1 (11.1%) subjects at week 12, respectively.…”

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Potestio¹,

Camela²,

Cacciapuoti³

et al. 2023

CCID

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, and tachycardia making this condition a possible life-threatening disease, particularly if appropriate treatments are not performed. In this scenario, effective and safe therapies are required. Unfortunately, the rarity of EP makes head-to-head Phase III trials challenging, leading to the lack of established guidelines for its management. Globally, conventional systemic drugs such as cyclosporine, methotrexate, and retinoids often have contraindications linked to patients' comorbidities and have not shown a high profile of efficacy and safety. Recently, the development of biologic drugs including anti-tumor necrosis factor-α and anti-interleukin 12-23, 23, and 17 has revealed favorable results for the management of plaque psoriasis, making them also a possible therapeutic option for EP disease. However, their use in EP is still offlabel. The aim of our study was to review current literature on the use of biologic drugs for the treatment of EPs in order to offer a wide perspective on their possible application in EP management.

show abstract

Section: Ixekizumabmentioning

confidence: 99%

Section: Dovepressmentioning

confidence: 99%

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Potestio¹,

Camela²,

Cacciapuoti³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…As other available options, there are anti-IL-17 agents, an essential interleukin in the pathophysiology of psoriasis. Secukinumab and ixekizumab, two anti IL17 and brodalumab, an IL-17R antagonist, have been reported to be useful and safe for treating EP [12][13][14]. The use of iL-23 inhibitors has also been considered, since it is essential for the proliferation of Th17 cells, with the advantage of lower risk of infection, such as Ustekinumab.…”

Section: Erythrodermic Psoriasismentioning

confidence: 99%

Untitled

2023

J Rheum Dis Treat

View full text Add to dashboard Cite

Erythrodermic psoriasis is a rare and life-threatening variant of psoriasis. Multiple triggering factors have been described, including emotional stress, alcohol consumption, medications, infections, less common phototherapy, photo chemotherapy, application of topical irritants, Sars-Cov 2 vaccine, HIV and hypocalcemia.In this paper we report the first case of a patient with a flare up of erythrodermic psoriasis whose only possible trigger was uncontrolled, undiagnosed diabetes mellitus. Psoriatic arthritis was concomitantly diagnosed. He was initially managed with supportive therapy, corticosteroids, and methotrexate with a poor response.Therefore, biological therapy with infliximab was started with a rapid clinical response and clearance of skin lesions, and resolution of joint pain. Conclusion:Poor glycemic control may be associated with erythrodermic flares of psoriasis. Treatment should be set up based on the severity of the presentation. Timely treatment with a TNF alpha inhibitor allows rapid resolution of symptoms.

show abstract

“…102 The results revealed that the effects were sustained to week 244, the mean PASI score was 42.8 at baseline, 3.0 at week 52, and 5.0 at week 244. There are also several case reports regarding the efficacy of ixekizumab for EP, [104][105][106] including one case with human immunodeficiency virus (HIV) infection. 106 For patients with prior failure with secukinumab, ixekizumab still demonstrated a rapid response as early as week 4.…”

Section: Ixekizumabmentioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

show abstract

Ixekizumab as treatment of erythrodermic psoriasis

Cited by 7 publications

References 14 publications

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Untitled

Updates on the Treatment of Erythrodermic Psoriasis

Contact Info

Product

Resources

About